2nd July - Statement From The Whittemore Peterson Institute - Regarding CDC Study

VillageLife

Senior Member
Messages
674
Likes
36
Location
United Kingdom
Whittemore Peterson Institute Statement regarding
Centers for Disease Control XMRV Study


Contrary to the WPI study published in Science in October, 2009, as well as studies done by
others, including the NIH and FDA, Mr. William Switzer of the Centers for Disease Control reported
that his research team was unable to detect XMRV in CFS patient samples. This negative finding is in contrast to the WPI study in which we detected XMRV in 67% of CFS patient samples.

To correctly replicate scientific studies it is imperative that researchers use the same methods
and patient criteria to ensure accurate results. The methodology used by the CDC was not the same as
that used in the WPI study nor was the patient selection criteria. In September 2009, WPI sent the CDC
twenty confirmed positive samples and the appropriate methodology to help them develop a clinically
validated test. However, this team chose not to do this.

Until researchers use clinically validated tests to detect XMRV in patient samples, as WPI
and their collaborators have successfully done, an accurate association of XMRV to any diseased
population cannot be made. For this reason, WPI researchers and many others are currently validating
more sensitive clinical assays to assist federal agencies in their search for the true prevalence of XMRV
in the human population.

WPI will continue its core mission to deliver answers to patients with neuro-immune diseases
by supporting the development of accurate diagnostics and providing effective therapeutics and clinical
care.
 

Rivotril

Senior Member
Messages
154
Likes
0
maybe they "use " the 67% number because thats the number that is officially confirmed in a peer reviewed paper. The later 95%+ percentages were found after additional studying but were never published in a scientific magazine. so in a kind of news release to "attack"the CDC thing, maybe they thought it would be better to use just the real scientifically confirmed percentage
 

Trooper

Senior Member
Messages
105
Likes
2
Location
UK
In September 2009, WPI sent the CDC twenty confirmed positive samples and the appropriate methodology to help them develop a clinically validated test. However, this team chose not to do this.
This bit made me smile ^^ :Retro smile:

Another well balanced statement from the WPI :thumbsup:
 

omerbasket

Senior Member
Messages
510
Likes
13
maybe they "use " the 67% number because thats the number that is officially confirmed in a peer reviewed paper. The later 95%+ percentages were found after additional studying but were never published in a scientific magazine. so in a kind of news release to "attack"the CDC thing, maybe they thought it would be better to use just the real scientifically confirmed percentage
I think that this is the exact reason as to why they used this number.
 

George

waitin' fer rabbits
Messages
851
Likes
80
Location
South Texas
Dr. Mikovitz said in one of her interviews (can't remember where) that the supplemental paper was being reviewed for publishing, this was back in March. It annoys the hell out of me that some twenty papers including the WPI's two additional papers are being held up but they publish this pap by the CDC.

Too much work has been done by too many good scientist. With the information out now by journalist that the DHHS has a hand in holding this information back I think the scientist themselves are starting to get a little pissed. I hope this set's off a firestorm.
 

dannybex

Senior Member
Messages
3,355
Likes
2,357
Location
Seattle
Yes...

I think that this is the exact reason as to why they used this number.
That's precisely the reason.

"This negative finding is in contrast to the WPI study in which we detected XMRV in 67% of CFS patient samples."

eta: perhaps they could have said "...the WPI study published in the journal Science..." ?
 

Daffodil

Senior Member
Messages
5,556
Likes
5,869
the last number i heard was 99% of the patient samples used in the science article have now tested positive.
 

*GG*

senior member
Messages
6,334
Likes
5,012
Location
Concord, NH
Please Research World, (this includes you taxpayer funded gov't entities),

Please DO YOUR JOB and help the sick get better! People have lost their lives to this horrible illness, some decades and decades, but some only YEARS! (Sarcasm). Meanwhile more people are becoming ill with this disease and will find that there are NO ANSWERS still after decades worth of "research".

Take this research world! and listen up!!

Until researchers use clinically validated tests to detect XMRV in patient samples, as WPI
and their collaborators have successfully done, an accurate association of XMRV to any diseased
population cannot be made.

For this reason, WPI researchers and many others are currently validating
more sensitive clinical assays to assist federal agencies in their search for the true prevalence of XMRV
in the human population.

Whittemore Peterson Institute Statement regarding
Centers for Disease Control XMRV Study


Contrary to the WPI study published in Science in October, 2009, as well as studies done by
others, including the NIH and FDA, Mr. William Switzer of the Centers for Disease Control reported
that his research team was unable to detect XMRV in CFS patient samples. This negative finding is in contrast to the WPI study in which we detected XMRV in 67% of CFS patient samples.

To correctly replicate scientific studies it is imperative that researchers use the same methods
and patient criteria to ensure accurate results. The methodology used by the CDC was not the same as
that used in the WPI study nor was the patient selection criteria. In September 2009, WPI sent the CDC
twenty confirmed positive samples and the appropriate methodology to help them develop a clinically
validated test. However, this team chose not to do this.

Until researchers use clinically validated tests to detect XMRV in patient samples, as WPI
and their collaborators have successfully done, an accurate association of XMRV to any diseased
population cannot be made. For this reason, WPI researchers and many others are currently validating
more sensitive clinical assays to assist federal agencies in their search for the true prevalence of XMRV
in the human population.

WPI will continue its core mission to deliver answers to patients with neuro-immune diseases
by supporting the development of accurate diagnostics and providing effective therapeutics and clinical
care.